ASCO 2024 abstract movers – Merus convinces, at first
Thursday's unveiling of regular ASCO abstract yielded a few initial winners and losers.
Immatics’ PRAME gift keeps on giving
The company dribbles out more data on IMA203, and the numbers head in the right direction.
Immatics builds on its PRAME success
PRAME has become a hot target for Immatics, which is now clinically progressing two different modalities against this antigen.